Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer?

Winston W. Tan, MD


December 21, 2021

According to the 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5), biological markers (especially HR and HER2) should be reassessed at least once in the metastatic setting if clinically feasible as discordance between primary biomarker profiles of primary and metastatic breast cancer is well documented. Depending on the metastasis site, technical considerations may need to be discussed with the pathologist.

Learn more about breast cancer treatment protocols.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.